<code id='809EC0A2BC'></code><style id='809EC0A2BC'></style>
    • <acronym id='809EC0A2BC'></acronym>
      <center id='809EC0A2BC'><center id='809EC0A2BC'><tfoot id='809EC0A2BC'></tfoot></center><abbr id='809EC0A2BC'><dir id='809EC0A2BC'><tfoot id='809EC0A2BC'></tfoot><noframes id='809EC0A2BC'>

    • <optgroup id='809EC0A2BC'><strike id='809EC0A2BC'><sup id='809EC0A2BC'></sup></strike><code id='809EC0A2BC'></code></optgroup>
        1. <b id='809EC0A2BC'><label id='809EC0A2BC'><select id='809EC0A2BC'><dt id='809EC0A2BC'><span id='809EC0A2BC'></span></dt></select></label></b><u id='809EC0A2BC'></u>
          <i id='809EC0A2BC'><strike id='809EC0A2BC'><tt id='809EC0A2BC'><pre id='809EC0A2BC'></pre></tt></strike></i>

          fashion

          fashion

          author:entertainment    Page View:3415
          From left, STAT's Allison DeAngelis, ALS advocate Cathy Collet, Yale's Gregg Gonsalves, Sick Cells' Ashley Valentine, and Canary Advisors' Jennifer McNary at a panel at the 2024 STAT Breakthrough Summit East. STAT

          NEW YORK — Over 30 years ago, Gregg Gonsalves and other AIDS activists persuaded Congress to create the accelerated approval pathway, allowing regulators to speed access to drugs for thousands of dying patients.

          These days, though, Gonsalves sounds uneasy — if not mournful — of the world he helped build. 

          advertisement

          “We’re approving drugs faster and faster — [the FDA is] one of the fastest regulatory agencies in the world — we know less and less about them, and we pay more and more for them,” said Gonsalves, now a professor at Yale, at STAT Breakthrough Summit East on Thursday. “So in that way, the system is not working. We basically put access out there as this talisman of hope, but we don’t compel the companies that give us answers about what these drugs do in our bodies.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Clinical trials giant ICON acquires HumanFirst
          Clinical trials giant ICON acquires HumanFirst

          AdobeAspharmacompanieswrestlewithhowandwhentousewearablesandotherdigitaltechnologiestomeasurehowthei

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          Readout Newsletter: Ironwood, Pfizer, FogPharma updates

          DavidLRyan/TheBostonGlobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourb